Compare DexCom, Inc. (DXCM) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hasbro, Inc. — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Hasbro, Inc. trades at $81.85 (market cap $11.39B). The key difference: DexCom, Inc. is far larger — about 2.5× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.48% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HAS | |
|---|---|---|
Market Cap | $28.06B | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $105.88 |
52-Week Low | $54.84 | $70.95 |
Enterprise Value | $27.03B | $13.66B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Hasbro (HAS) trades at $81.65, up 4.12% today, but remains in a bearish technical trend. The company reported negative net income of -$322.40M for 2025 despite revenue growth to $4.70B, with profitability metrics like ROE at -24.49% reflecting challenges. Recent news highlights product innovation like Blooms by Play-Doh targeting adults, while earnings have consistently beaten expectations in recent quarters, suggesting potential operational resilience amid financial headwinds.
The outlook is mixed: analyst consensus is bullish with a $105.43 price target (51.52% buy ratings), but high debt and negative margins pose risks. Upside hinges on earnings turnaround and successful adult-focused product launches, while competitive pressures and macroeconomic factors could hinder recovery. Investors should weigh strong analyst sentiment against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
